Gelesis
Biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Learn more
Launch date
Employees
Market cap
$154k
Enterprise valuation
$54m (Public information from Sep 2024)
Share price
$0.0021 GLSHQ
Boston Massachusetts (HQ)
Authorizing premium user...